Skip to main content Accessibility help
×
Home

Significance of serum vascular endothelial growth factor and cancer antigen 15.3 in patients with triple negative breast cancer

  • Priyanka Chanana (a1), Awadesh Kumar Pandey (a2), Budhi Singh Yadav (a3), Jasbinder Kaur (a4), Seema Singla (a4), Kislay Dimri (a5), Romeeta Trehan (a5) and Pawan Krishan (a6)...

Abstract

Background

A pilot study was undertaken to find significance of vascular endothelial growth factor (VEGF) and cancer antigen (CA 15.3) in breast cancer patients.

Materials and methods

Total 70 patients with breast cancer were divided into triple negative breast cancer (TNBC) and non-TNBC depending on oestrogen receptors, progesterone receptors or HER-2/neu receptors status. Serum CA 15.3 and VEGF levels were evaluated with enzyme-linked immunosorbent assay at the time of diagnosis and were correlated with age, tumour size and stage of the disease in both the groups. Spearman's test was used to find the correlation.

Results

VEGF levels were found to be >400 pg/ml in 27 patients, 19 (54·33%) of them were TNBC and only 8 (22·87%) non-TNBC. Mean values of the VEGF were, 784·34 pg/ml in TNBC and 334·60 pg/ml non-TNBC patients, respectively. CA 15.3 level was found to be higher in non-TNBC group (60·72 U/ml) than in TNBC group (45·24 U/ml). In all patients significant correlation was found between serum CA 15.3 level and tumour size and stage of the disease. In non-TNBC patients significant correlation was seen between CA 15.3 values and stage of the disease, but VEGF had no correlation with any of the disease parameters. In TNBC patients, there was no correlation between CA 15.3 level and any of the disease parameters but VEGF showed a significant correlation with both tumour size and stage of the disease.

Conclusion

Expression profile of VEGF was high in TNBC than non-TNBC patients. VEGF serves to be a better biomarker as compared with CA 15.3 in TNBC patients.

Copyright

Corresponding author

Correspondence to: Dr Budhi Singh Yadav, Department of Radiation Oncology, Regional Cancer Centre, Post Graduate Institute of Medical Education & Research, Sector–12, Chandigarh, India. Tel: +91 981 598 1176. E-mail: drbudhi@gmail.com

References

Hide All
1.Dent, R, Trudeau, M, Pritchard, K Iet al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 44294434.
2.Kreike, B, Van Kouwenhove, M, Horlings, Het al. Gene expression profiling and histopathological characterization of triple-negative/basallike breast carcinomas. Breast Cancer Res 2007; 9: R65.
3.Livasy, C A, Karaca, C, Nanda, Ret al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264271.
4.Foulkes, W D, Smith, I E, Reis-Filho, J S. Triple-negative breast cancer. N Engl J Med 2010; 363: 19381948.
5.Cleator, S, Heller, W, Coombes, R C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235244.
6.Irwin, W J Jr, Carey, L A. What is triple negative breast cancer. Eur J Vancer 2008; 44: 27992805.
7.Stockmans, G, Deraedt, K, Wildiers, Het al. Triple negative breast cancer. Curr Opin.Oncol. 2008; 20: 614620.
8.Reis-Filho, J S, Tutt, A N. Triple negative tumours: a critical review. Histopathology 2008; 52: 108118.
9.Diaz, L K, Cryns, V L, Symmans, F, Sneige, N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007; 14: 419430.
10.Perou, C M, Sørlie, T, Eisen, M Bet al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747752.
11.Patil, V W, Singhai, R, Patil, A Vet al. Triple-negative (ER, PgR, HER 2/neu) breast cancer in Indian women. Breast Cancer: Targets and Therapy 2011; 3: 919.
12.Longacre, T A, Bartow, S A. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382.
13.Rodriguez-Pinilla, S M, Sarrio, D, Honrado, Eet al. Prognostic significance of basal-like phenotype and fascin expression in nodenegative invasive breast carcinomas. Clin Cancer Res 2006; 12: 15331539.
14.Liedtke, C, Mazouni, C, Hess, K Ret al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 12751281.
15.Hayes, D F, Thor, A D, Dressler, L Get al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357: 14961506.
16.Kassam, F, Enright, K, Dent, Ret al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009; 9: 2933.
17.Roche, H, Li, R, Ro, Jet al. Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. Poster presentation at the San Antonio Breast Cancer Symposium (SABCS), 10–14 Dec 2008 (Abstr 2015), San Antonio, TX.
18.Farmer, H, McCabe, N, Lord, C Jet al. Targeting the DNA repair defect in BRCA1 mutant cells as a therapeutic strategy. Nature 2005; 434: 917921.
19.Garber, J F, Richardson, A, Harris, L N. Neo-adjuvant cisplatin (CDDP) in ‘triple negative’ breast cancer (BC) [abstract 308]. Breast Cancer Res Treat 2006; 100 (suppl 1, Abstract 308 S32.
20.Duffy, M J, Duggan, C, Keane, Ret al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004; 50: 35593563.
21.Taha, F M, Zeeneldin, A A, Amani, Met al. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem 2009; 42: 14201426.
22.Khafagy, W, Aref, S, Zalata, K. Association of serum vascular endothelial growth factor level with estrogen receptors status in breast cancer patients. Egypt J Surg 2005; 24 (4): 188194.
23.Heer, K, Kumar, H, Speirs, Vet al. Preoperative serum VEGF in primary breast cancer patients – its relation with oestrogen receptor status and cancer type. Eur J Cancer 1998; 34 (5): S29.
24.Derya, D, Hakan, C, Hilal, S O, Duygu, D, Vidan, Y. Serum levels of angiogenic factors in early breast cancer remain close to normal. The Breast 2009; 18: 2629.
25.Linderholm, B K, Helborg, H, Johansson, Uet al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009; 20: 16391646.
26.Verheul, H M, Pinedo, H M. The importance of platelet counts and their contents in cancer. Clin Cancer Res 2003; 7: 32193221.
27.Wynendaele, W, Derua, R, Hoylaerts, M Fet al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 1999; 10: 965971.
28.Lee, J K, Hong, Y J, Han, C Jet al. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol 2000; 17: 149152.
29.Park, B W, Oh, J W, Kim, J Het al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008; 19: 675681.
30.Martin, A, Corte, D, Alvarez, A Met al. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res 2006; 26: 39653972.
31.Velaiutham, S, Taib, N A, Ng, K L, Yoong, B K, Yip, C H. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer? Asian Pac J Cancer Prev 2008; 9: 445448.
32.Agrawal, A K, Jelen, M, Rudnicki, Jet al. The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type. Folia Histochemica et Cytobiologica 2010; 48 (1): 2629.
33.Berruti, A, Tampelllini, M, Torta, Met al. Prognostic value in predicting overall survival of two mucinous markers; CA 15.3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994; 30A: 20822084.
34.Laessig, D, Nagel, D, Heinemann, Vet al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 2007; 27: 19631968.
35.Ferrero, S, Nicoletti, A, Ragni, N. Letter to the editor: measurement of serum vascular endothelial growth factor in breast cancer patients. Intern Med J 2005; 35: 310314.
36.Inai, T, Mancuso, M, Hashizume, Het al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 3552.
37.Jain, R K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 5862.
38.Diaz, L K, Cryns, V L, Symmans, F, Sneige, N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007; 14: 419430.
39.Miller, K, Wang, M, Gralow, Jet al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 26662676.

Keywords

Significance of serum vascular endothelial growth factor and cancer antigen 15.3 in patients with triple negative breast cancer

  • Priyanka Chanana (a1), Awadesh Kumar Pandey (a2), Budhi Singh Yadav (a3), Jasbinder Kaur (a4), Seema Singla (a4), Kislay Dimri (a5), Romeeta Trehan (a5) and Pawan Krishan (a6)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed